What are the recent advances in fecal microbiota therapy?

Pr. Peter KonturekProf. Peter C. Konturek from Thuringia Clinic Saalfeld, Teaching Hospital of the University of Jena, Germany will present the recent advances on fecal microbiota therapy during Targeting Microbiota World Congress 2017.

 

What is FMT?
Fecal microbiota transplantation (FMT) is the administration of liquid filtrate feces from a healthy donor into the gut of a recipient to cure a specific disease. This method has gained mainstream attention with its remarkable efficiacy in treating recurrent Clostridium difficile infection (CDI) by restoration of healthy gut microbiota. Previous studies including our own demontrated a high cure rate of 90% in patients with recurrent CDI.

Why using FMT?
Another area of interest for this method is the treatment of inflammatory bowel disease (IBD) that is characterized by reduced richness and diversity of gut microbiota (IBD-related dysbiosis). Recently, two randomized controlled trials exploring the use of FMT for treatment of IBD were published, However, the results are discrepant due to methodological differences. There is an increasing evidence that FMT could be a useful method in certain subset of patients with IBD. (...)

For more information, don't hesitate to attend Targeting Microbiota World Congress.

 


Who is Pr. Peter Konturek?

Pr. Konturek is a Professor of Internal Medicine and Gastroenterology at the University Erlangen-Nuremberg in Germany and Head of the Department of Internal Medicine at the Thuringia Clinic Saalfeld, Teaching Hospital of the University of Jena since 2010.

Among his different memberships:

  • Fellow of the American Association of Gastroenterology (AGAF)
  • German Association of Gastroenterology (DGVS)
  • Bavarian Association of Gastroenterology (BGFG)
  • German Association of Internal Medicine (DGIM)

His researches are focused on the impact of H.pylori infection in the pathogenesis of peptic ulcer disease and gastric cancer, pathogenesis of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), but also the role of microbiota in the gastrointestinal tract and interaction with the brain-gut-axis, effect of stress on gastrointestinal functions.

His clinical focus is about the diagnostic and interventional endoscopy, treatment of IBD and IBS patients in a special outpatient clinic, therapy of food allergy and intolerances, fecal microbiota transplantation.

He published more than 250 original peer-reviewed publications and more than 15 book chapters. He is also member of the Editorial Board of the World Journal of Gastroenterology a,d reviewer of the leading gastroenterological journals.

Visit Berlin

visit berlin